Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480658 | 1.00 | KCNH2 (0.55) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL22609255 | 0.92 | KCNH2 (0.56) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL519168 | 0.91 | DRD2 (0.58) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL31493409 | 0.90 | ALDH1A1 (0.56) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL4937120 | 0.89 | HRH3 (0.57) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL6228523 | 0.88 | MAPT (0.65) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL28180194 | 0.87 | HRH3 (0.60) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL28180989 | 0.87 | HRH3 (0.60) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL28180977 | 0.87 | HRH3 (0.60) | KCNH2DRD2DRD4DRD3MAPT | |
| SCHEMBL17971426 | 0.87 | HRH3 (0.60) | KCNH2DRD2DRD4DRD3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050279030-A1 | CMP formulations | SAINT-GOBAIN CERAMICS & PLASTICS, INC. (US) | 2005-12-22 | — | — | US | claimed |
| EP-4745138-A1 | THIO-GLUTARIMIDO ISOINDOLINONE DERIVATIVE, BIFUNCTIONAL PROTEIN DEGRADER CONTAINING SAME, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| EP-4678638-A1 | NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-12 | — | — | US | disclosed |
| CN-119529854-A | Liquid crystal alignment agent, manufacturing method thereof, liquid crystal alignment film and liquid crystal display assembly | 奇美实业股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-02-11 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-0245997-B1 | N-SUBSTITUTED P-AMINOETHYLSULPHON ANILIDES AS ANTIARRHYTHMIC AGENTS, AND INTERMEDIATES THEREFOR | Pfizer Limited (GB) | 1992-04-15 | — | — | EP | disclosed |
| US-5079248-A | Antifibrillatory agents; side effect reduction | PFIZER INC. (US) | 1992-01-07 | — | — | US | disclosed |
| EP-0431943-A2 | Nitrogen-containing spirocycles | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-5006561-A | Indane sulfonamide anti-arrhythmic agents and use | PFIZER INC. (US) | 1991-04-09 | — | — | US | disclosed |
| US-4959366-A | Anti-arrhythmic agents | PFIZER INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0355492-A1 | Reactive dyes | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0286278-A1 | Indanamine derivatives useful as antiarrhythmic agents | Pfizer Limited (GB) | 1988-10-12 | — | — | EP | disclosed |
| EP-0245997-A2 | N-substituted p-aminoethylsulphon anilides as antiarrhythmic agents, and intermediates therefor | Pfizer Limited (GB) | 1987-11-19 | — | — | EP | disclosed |
| EP-0209763-A1 | Salts of morpholiniocarboxylic esters and morpholinioalkyl-phenylethers, processes for their preparation, and their use as fungicides | Institut für Pflanzenschutzforschung Kleinmachnow der A.d.L. der DDR (DD) | 1987-01-28 | — | — | EP | disclosed |
| US-3951987-A | PSYCHOSEDATIVE | HOFFMANN-LA ROCHE INC. (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | KCNH2 4657/4885DRD2 4503/4885DRD4 3271/4885 |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | WEE1, WEE2, NME1 | KCNH2 4429/4885DRD2 4872/4885DRD4 4879/4885 |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | KCNH2 4429/4885DRD2 4872/4885DRD4 4879/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | KCNH2 4657/4885DRD2 4503/4885DRD4 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.